Table 2.

Safety and efficacy of aspirin in CKD

Study	Study Type	Participants	N	Efficacy	Safety
UK-HARP (25)	RCT	Predialysis CKD; chronic dialysis; renal transplant	448	Not analyzed in this study	No evidence of major bleeding; 3-fold risk of minor bleeding
DOPPS (26)	Nested case control study of DOPPS 1–2	Randomly selected chronic HD patients	28,320	No benefit on all-cause mortality; reduced risk of MI and stroke	No increase in GI bleeds
Sciahbasi et al. (27)	Retrospective analysis	Patients admitted to community hospital with ACS	595	Patients on chronic low-dose aspirin and statin are less likely to get admitted with STEMI	Not analyzed
Palmer et al. (28)	Meta-analysis	9 trials on ACS/PCI; 31 trials on stable or no CAD	21,670	Little or no effect on all-cause mortality; uncertain effects on cardiovascular mortality	Increase in major and minor bleeding; uncertain risk of hemorrhagic stroke

UK-HARP, First United Kingdom Heart and Renal Protection study; RCT, randomized controlled trial; DOPPS, Dialysis Outcomes and Practice Patterns Study; HD, hemodialysis; MI, myocardial infarction;; GI, gastrointestinal; ACS, acute coronary syndrome; STEMI, ST elevation myocardial infarction; PCI, percutaneous coronary intervention; CAD, coronary artery disease.